FOLH1 and prostate cancer: Heetman, Paulino Pereira, Kelder, Soeterik, Wever, Lavalaye, van der Hoeven, Lam, van Melick, van den Bergh et al. explored PSMA-PET’s utility in differentiating aggressive prostate cancer, focusing on its capability to inform treatment decisions.